Paris , 29 May 2018 - Ipsen today announced that cabozantinib and irinotecan liposome injection are the subject of 8 presentations at the 2018 American Society of Clinical.
- Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma - Paris , 04 July.
The combination of a tyrosine kinase inhibitor with an immune checkpoint inhibitor significantly improved progression-free survival in patients with hepatocellular carcinoma, shows a new study.